Retatrutide

Retatrutide is a synthetic peptide engineered as a balanced agonist of three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide 1 (GLP-1) receptor, and the glucagon receptor ([Jastreboff et al., *N Engl J Med* 2023, 389:514–526](https://doi.org/10.1056/NEJMoa2301972)). The first two receptors share their incretin mechanism with tirzepatide and semaglutide, respectively; the addition of glucagon-receptor agonism is what distinguishes retatrutide and is hypothesized to add a pro-energy-expenditure component to the appetite-suppressive and insulin-sensitizing effects of the two incretins. Mechanistically, glucagon-receptor agonism increases hepatic glucose output, mobilizes lipids, and raises basal energy expenditure — a combination that, balanced correctly against the incretin signals, is intended to drive weight loss through both reduced energy intake and increased energy turnover. The fatty-acid modification for albumin binding produces a roughly week-long pharmacokinetic profile suited to weekly dosing.

Retatrutide is the metabolic peptide where pharmacology is most actively expanding. The published Phase 2 trial (Jastreboff et al., *NEJM* 2023) randomized 338 adults with obesity to weekly retatrutide (1, 4, 8, or 12 mg) or placebo for 48 weeks. Mean weight change at 48 weeks was -8.7%, -17.1%, -22.8%, and -24.2% on the four doses versus -2.1% on placebo. At the 12-mg dose, every participant achieved at least 5% weight loss, 93% achieved at least 10%, and 83% achieved at least 15% — exceeding the response-rate envelope set by the SURMOUNT-1 tirzepatide trial. Cardiometabolic improvements followed the weight loss; 72% of participants who had prediabetes at baseline reverted to normoglycemia. Heart-rate increases peaked at 24 weeks and then declined toward baseline. Adverse events were dominated by transient mild-to-moderate gastrointestinal symptoms during dose escalation, consistent with the GLP-1 / GIP–GLP-1 class. The honest framing has two parts. First, the headline Phase 2 numbers are the most striking obesity-pharmacotherapy results published to date. Phase III trials (SURMOUNT-OB, TRIUMPH program in T2D and metabolic dysfunction-associated steatotic liver disease) are ongoing or being analyzed; preliminary disclosures continue to support the Phase 2 efficacy signal. Second, retatrutide remains an investigational agent. Off-label or compounded retatrutide that exists in the practitioner market today is sourced outside the regulatory approval pathway, with all of the sourcing-quality concerns the site declines to relitigate but that readers should weight heavily. The credibility of the Phase 2 trial does not transfer to a compounded supply. The longer-horizon safety questions are also less mature than for semaglutide or tirzepatide. The glucagon-receptor agonism component is genuinely new in human chronic dosing, and the long-tail signals that decades of GLP-1-class use have ruled in or out (or not) — pancreatitis incidence patterns, NAION, gastroparesis, suicidal ideation — are still being built for retatrutide.